SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytokine1 who wrote (8278)10/1/2000 5:29:07 PM
From: Arthur Radley  Read Replies (1) of 9719
 
Cytokine,
With your handle you need to add Inkine(INKP) to your portfolio. Granted! Inkine's newly approved drug isn't rocket science material ....but will it be a money maker! I think ...YES!
Colon cancer is second leading cause of cancer-related deaths in the U.S. To address this growing concern, it is estimated that here in the U.S. 7.5million colonoscopies will be performed. By 2003, this number will grow to 10 million and to 24 million worldwide.
One process has to take place before these colonscopies are performed....cleanse the colon for an unobstructed view of the colon. Until INKINE's purgative pill was approved, the method of cleansing was by drinking four liters of polyethylene-glycol electrolyte solution or drink 90ml of a bitter tasting sodium phosphate solution.

Now which process would you think patients undergoing colonscopies will select. Taking a few pills with water or either of the above.
INKP's CEO will be on Power Lunch tomorrow(CNBC).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News